Table of Contents Table of Contents
Previous Page  717 / 812 Next Page
Information
Show Menu
Previous Page 717 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S713

EV1139

Depressive syndrome in

schizophrenia and cannabis use

S. Bouri

1 ,

, H. zemmama

2

, K. El Ayoubi

2

, M.A. Berraho

3

,

A. Abdellaoui

4

, S. Achour

5

, I. Rammouz

2

1

Faculty of Science, Dhar El Mahraz, Laboratory Physiology,

Pharmacology & Environmental Health, Fez, Morocco

2

Faculty of medicine, Clinical neurosciences laboratory, Fez, Morocco

3

Faculty of medicine, Epidemiology Public Health, Fez, Morocco

4

Faculty of Science, Laboratory Physiology,Pharmacology &

Environmental Health, Fez, Morocco

5

University Hospital Hassan II, Toxicology Unit, Fez, Morocco

Corresponding author.

Introduction

Cannabis use is frequently observed in schizophre-

nia. Several medical and organic factors can lead to this

comorbidity. These include depressive symptoms.

Objective

Assessing the prevalence of depressive symptoms

within a population of schizophrenic inpatients and the association

with cannabis use.

Method

A group of 403 patients diagnosed with schizophrenia

according to Diagnostic and Statistical Manual of Mental Disorders,

4th Edition (DSM-IV), were assessed by The Calgary Depression

Scale for Schizophrenia (CDSS) scale measure depressive symptom

in schizophrenia. Socio-demographic, clinic, and urine toxicology

screens testing data were collected.

Results

The Schizophrenic patients included in this study have

an average age of 33 years. The majority of them are males (90%),

single (76%) and unemployed (72%). A total of 38 patients (9,4%)

have depressive symptoms (scored 6 or more on the CDSS). Among

this group, 16 patients (42,1%) were tested positive for cannabis

used. Although there is a high proportion of cannabis use among

patients with depression symptoms, there was no significant cor-

relation between the CDSS total score and cannabis use among

schizophrenic patients.

Conclusion

Depression is well known to occur during the course

of schizophrenia in many patients and contributes substantially to

the morbidity. Studies are needed that include correlation analyses

between depression and cannabis use in schizophrenia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2124

EV1140

A comprehensive systematic

screening protocol for assessment of

medical comorbidities in

schizophrenia

P. Bucci

1 ,

, E. Durante Mangoni

2

, P.C. Pafundi

2

, S. De Simone

1

,

U. Malgeri

2

, A. Mucci

1

, S. Galderisi

1

, M. Maj

1

1

University of Naples SUN, Department of Psychiatry, Naples, Italy

2

University of Naples SUN, Internal Medicine Section, Department of

Cardiothoracic Sciences, and Division of Infectious and Transplant

Medicine, Naples, Italy

Corresponding author.

Introduction

Difficult access and low quality of health care are

recognized as factors that may account for the excess deaths widely

reported in patients with schizophrenia. As a matter of fact, psychi-

atrists not always possess adequate competences in the assessment

of physical health, while non-psychiatric physicians receive little

training in psychiatry and are not prepared to take care of subjects

with severe mental illnesses.

Objectives

We present a comprehensive and systematic algo-

rithm for screening medical comorbidities, conceived to be easy

to use for psychiatrists, after a brief training.

Aims

The study is aimed to implement an instrument for proper

detection and management of physical illnesses in people with

schizophrenia.

Methods

The screening protocol, developed by internal medicine

specialists, was applied to 15 subjects in two independent assess-

ments, one performed by trainees in psychiatry, after a brief

training, and one carried out by one specialist and two trainees

in internal medicine. The analysis of the inter-rater reliability was

carried out by calculating the Cohen’s kappa coefficient and the

intraclass correlation coefficient as appropriate.

Results

The agreement among raters resulted excellent for 61%

of items, good for 17%, moderate for 18% and scarce for 4%. The few

items showing scarce inter-rater reliabilitywere excluded. The final

algorithm is being tested for feasibility in psychiatric settings.

Conclusions

The proposed screening protocol resulted in a suit-

able tool, showing moderate to excellent inter-rater reliability, that

can be used in clinical practice by psychiatrists after a brief training.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2125

EV1141

Depot aripiprazole as an alternative to

the oral formula

M.R. Calero Fernandez

Hospital Gutierrez Ortega, Unidad de Salud Mental, Valdepenas,

Spain

Background

Aripiprazole depot was launched in Spain in March

2015. American double blind studies with placebo showed a signif-

icant delay in relapse and a good tolerance profile with injectable

aripiprazole, with similar results to those obtained in studies com-

paring placebo and paliperidone depot.

Objective

To compare the self-perceived changes after de substi-

tution of oral paliperidone to depot formula.

Type of study

Descriptive, case series.

Sample

Ten patients. Age range: 22–62 years (mean age:

41.2 years). Seven men + 3 women. Inclusion criteria: diagnosis

of schizophrenia or schizoaffective disorder, no acute psychotic

symptons. Prior treatment with oral aripiprazole (average dose:

17.5mg) 20% on monotherapy of aripiprazol Oral aripiprazol was

switched to the deport formula; 60% received a dose of 400mg/28

days and 40% received 300mg/28 days intramuscularly.

Results

One patient abandoned the treatment after the first injec-

tion. Instrument for Assessment: IAQ scale: consists of 10 items;

we did not consider the items “prolactin level” and “akathisia” (no

patient showed neither before or after the treatment). The items

were rated by the patient: 1 (much better thanwith oral treatment),

2 (somewhat better), 3 (equal), 4 (worse) and 5 (much worse) aver-

ages scores: Positive symptoms: 1.25 Negative Symptoms: 1.75

Drowsiness: 1875 Weight gain: 1.625 extrapyramidalism: 1.875

Cognition: 1.625 Energy: 1.5 mood: 1625 total score media: 13.25

out of 40 (corresponding to the worst maximum score), 1.65 aver-

age per item.

Conclusion

Depot aripiprazole can be an alternative to the oral

formula. The sample showed a self perceived improvement of their

general state from “much better” to “somewhat better” than with

oral treatment.

Disclosure of interest

The author has not supplied his/her decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2126